Searchable abstracts of presentations at key conferences in endocrinology

ea0056p849 | Pituitary - Clinical | ECE2018

Real-world data from NordiNet International Outcome Study (IOS) and ANSWER Program provide new insights into the safety of growth hormone in a large cohort of children with Noonan Syndrome

Dahlgren Jovanna , Pedersen Birgitte Tonnes , Roehrich Sebastian , Abuzzahab M. Jennifer

Objectives: Congenital heart disease, especially pulmonary stenosis, is a frequent comorbidity in patients with Noonan syndrome (NS). Patients with NS are also at increased risk of childhood leukaemia and solid tumours. Among solid tumours, brain tumours, including glioneuronal tumours, have been described in younger patients but remain rare. Current safety data do not indicate an association of growth hormone (GH) therapy with increased risk for development or progression of ...